472 related articles for article (PubMed ID: 10582137)
21. Challenging the platinum combinations in the chemotherapy of NSCLC.
Douillard JY; Eckardt J; Scagliotti GV
Lung Cancer; 2002 Dec; 38 Suppl 4():21-8. PubMed ID: 12480191
[TBL] [Abstract][Full Text] [Related]
22. [Platinum-free gemcitabine-based combinations: an alternative to conventional chemotherapy of non-small-cell lung cancers?].
Pujol JL; Choma D; Jacot W; Quantin X
Bull Cancer; 2002 Aug; 89 Spec No():S85-90. PubMed ID: 12449036
[TBL] [Abstract][Full Text] [Related]
23. Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Pallis AG; Syrigos K; Kotsakis A; Karachaliou N; Polyzos A; Chandrinos V; Varthalitis I; Christophyllakis C; Ardavanis A; Vamvakas L; Vardakis N; Saridaki Z; Samonis G; Giassas S; Georgoulias V; Agelaki S
Clin Lung Cancer; 2011 Mar; 12(2):100-5. PubMed ID: 21550556
[TBL] [Abstract][Full Text] [Related]
24. [Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
Morere JF
Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S37-41. PubMed ID: 11924242
[No Abstract] [Full Text] [Related]
25. Docetaxel (taxotere) in the treatment of non-small cell lung cancer.
Georgoulias V
Curr Med Chem; 2002 Apr; 9(8):869-77. PubMed ID: 11966449
[TBL] [Abstract][Full Text] [Related]
26. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
Bunn PA
Semin Oncol; 1999 Feb; 26(1 Suppl 4):25-30. PubMed ID: 10201518
[TBL] [Abstract][Full Text] [Related]
27. [Gemcitabine].
Takeda K
Nihon Rinsho; 2002 May; 60 Suppl 5():359-65. PubMed ID: 12101689
[No Abstract] [Full Text] [Related]
28. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
Hosoe S; Komuta K; Shibata K; Harada H; Iwamoto Y; Ohsaki Y; Morioka T; Origasa H; Fukushima M; Furuse K; Kawahara M
Br J Cancer; 2003 Feb; 88(3):342-7. PubMed ID: 12569374
[TBL] [Abstract][Full Text] [Related]
29. Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Tumolo S; Toffoli G; Saracchini S; Lo Re G; Bruschi G; Boccieri MG
Lung Cancer; 2001 Dec; 34 Suppl 4():S37-46. PubMed ID: 11742701
[TBL] [Abstract][Full Text] [Related]
30. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
Bunn PA; Kelly K
Clin Cancer Res; 1998 May; 4(5):1087-100. PubMed ID: 9607565
[TBL] [Abstract][Full Text] [Related]
31. The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
Waters JS; O'Brien ME
Br J Cancer; 2002 Aug; 87(5):481-90. PubMed ID: 12189541
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
Khuri FR
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
[TBL] [Abstract][Full Text] [Related]
33. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
[TBL] [Abstract][Full Text] [Related]
34. [Developed new agents for lung cancer].
Kato Y; Saijo N
Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):218-23. PubMed ID: 11904983
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.
Vokes EE; Herndon JE; Crawford J; Leopold KA; Perry MC; Miller AA; Green MR
J Clin Oncol; 2002 Oct; 20(20):4191-8. PubMed ID: 12377962
[TBL] [Abstract][Full Text] [Related]
36. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
Pujol JL; Barlesi F; Daurès JP
Lung Cancer; 2006 Mar; 51(3):335-45. PubMed ID: 16478643
[TBL] [Abstract][Full Text] [Related]
37. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
Aapro MS
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):46-9. PubMed ID: 9364543
[TBL] [Abstract][Full Text] [Related]
38. Rationale for non-platinum chemotherapy in advanced NSCLC.
Murren JR
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
[TBL] [Abstract][Full Text] [Related]
39. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
Tas F; Demir C; Camlica H; Ustuner Z; Topuz E
Med Oncol; 2004; 21(3):233-40. PubMed ID: 15456950
[TBL] [Abstract][Full Text] [Related]
40. Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent phase II studies.
Kosmas C; Tsavaris N; Kalofonos HP
Med Sci Monit; 2002 Jun; 8(6):PI58-63. PubMed ID: 12070450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
